Everett leads the commercial organization at Cognito Therapeutics, a pioneer in non-invasive optogenetics to treat neurodegenerative diseases and improve human cognitive performance. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. As Chief Commercial Officer, Everett leads Cognito's commercial readiness, marketing, sales, and health economic evidence development for the company’s breakthrough treatment portfolio. Everett was previously CCO at AppliedVR and VP of Market Access, Reimbursement & Government Affairs at Pear Therapeutics.